<DOC>
	<DOCNO>NCT02477397</DOCNO>
	<brief_summary>Study investigate effect symptom-driven maintenance reliever therapy COPD .</brief_summary>
	<brief_title>Symptom-driven Maintenance Reliever Treatment Prevent Exacerbations COPD</brief_title>
	<detailed_description>Rationale : Chronic obstructive pulmonary disease ( COPD ) lead cause death worldwide morbidity mortality still rise . A symptom-driven maintenance reliever therapy ( SMART ) budesonide/formoterol frequently use treatment strategy asthma . Several study show SMART approach effectively reduce number asthma exacerbation compare fixed maintenance dose , e.g . fluticasone/salmeterol . In addition , large improvement lung function symptom observe asthma patient SMART approach . Thus far , study investigate efficacy SMART approach patient COPD . The investigator hypothesize SMART treatment budesonide/formoterol effective fluticasone/salmeterol fix dose treatment COPD . Objective : This research proposal aim investigate efficacy SMART approach budesonide/fomoterol versus fix dose treatment fluticasone/salmeterol patient COPD . Study design : This randomize , parallel 2-arm , open-label , multi-centre study . Study population : A total 260 COPD patient include smoke history &gt; 10 pack year , FEV1 &lt; 80 % predict either use inhaled corticosteroid least one COPD exacerbation 2 year prior inclusion . Intervention : COPD patient randomize one follow two treatment group : A : One year Spiromax® budesonide/formoterol 160/4.5 μg two inhalation twice daily + Spiromax® budesonide/formoterol 160/4.5 μg need maximum 8 inhalation daily . B : One year Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg need maximum 8 inhalation daily . Main study endpoints/objectives : The primary endpoint reduction number COPD exacerbation require treatment oral prednisolone ) . Nature extent burden risk associate participation , benefit group relatedness : This study specific benefit participate patient . The study also major risk . Minor risk participant study : - Nasal epithelium collection may cause temporary nose bleed . - Blood collection may cause bruising . - All drug may cause side effect . The combination treatment inhaled corticosteroid long-acting β2-agonist : budesonide/formoterol fluticasone/salmeterol medicinal product market many year many country often prescribe asthma COPD .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Age 40 80 year Smoking history &gt; 10 pack year COPD patient FEV1 &lt; 80 % predict either use inhaled corticosteroid . At least one COPD exacerbation oral prednisolone prescribe 2 year prior inclusion study History asthma . Exacerbation respiratory tract infection last 4 week prior randomization . Females childbearing potential without efficient contraception unless meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH &gt; 40 mIU/mL use one follow acceptable method contraception : 1 . Surgical sterilization ( e.g . bilateral tubal ligation , hysterectomy ) . 2 . Hormonal contraception ( implantable , patch , oral , injectable ) . 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/cream/suppository . 4 . Continuous abstinence . Periodic abstinence ( e.g . calendar , ovulation , symptomthermal , postovulation method ) withdrawal acceptable method contraception . Reliable contraception maintain throughout study 30 day study drug discontinuation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Spiromax</keyword>
	<keyword>Budesonide/formoterol</keyword>
	<keyword>COPD</keyword>
	<keyword>exacerbation</keyword>
	<keyword>SMART</keyword>
</DOC>